Hanako meets a patient with heart failure, a man in his 50s. He told Huazi that the doctor let him take Sakuba tridan, the price of this medicine is not cheap, is it really necessary to take it, is there any other medicine that can be replaced?
Huazi told him that sacobatridan is the world's first marketed angiotensin receptor cerebrorinpeptase inhibitor (ARNI), a first-line drug for chronic heart failure, can also be used to treat high blood pressure, and there is currently no other drug that can be replaced. For as long as economic conditions permit, it should remain in the drug regimen.
<h1 class="pgc-h-arrow-right" data-track="3" > Heart failure is the terminal stage of all heart disease</h1>
Hanako told the patient to understand the severity of heart failure. This is a progressive disease in which heart function decreases due to various heart diseases, the main cause of which is high blood pressure. After the decline in heart function, blood flow back and heart ejaculation will be affected, and various organs of the body will be dysfunctional due to insufficient blood supply.
Heart failure is the terminal stage of all heart diseases and is similar to the mortality rate for malignant tumors, with a 5-year mortality rate of 50%. Therefore, once heart failure occurs, it must not be taken lightly, and it is necessary to actively treat, control disease progression, prolong survival and improve quality of life.
<h1 class="pgc-h-arrow-right" data-track="22" > second, the "golden triangle" in the treatment of heart failure</h1>
The treatment of heart failure has a "golden triangle" combination, which refers to the combination of three types of drugs.
The first class of drugs are pry drugs and sartans, which inhibit the renin-angiotensin-aldosterone system (RAAS), delay ventricular remodeling, prevent ventricular enlargement, and are the cornerstone of heart failure.
The second class of drugs is a lore class of drugs, which inhibit cardiac excitability, reduce the stimulation of catecholamine hormones on the heart, and reduce the incidence of sudden death.
The third class of drugs are aldosterone receptor antagonists, which fight the water-sodium retention effect caused by aldosterones, and can be combined with other drugs to delay disease progression and reduce the risk of death.
<h1 class="pgc-h-arrow-right" data-track="23" >3, Shakuba Trisansartan can be used as a new member of the "Golden Triangle"</h1>
The human heart and vascular endothelial cells can secrete natriuretic peptides, produce natriuretic diuretics, inhibit aldosterone secretion, inhibit RAAS, inhibit myocardial fibrosis and other effects. However, the naturally secreted natriuretic peptides are quickly degraded by enzymes and have a short duration of action, while sakubatre is a cerebrocarprotein inhibitor that can inhibit the degradation of natriuretic peptides, increase their concentration, and enhance their effect.
In the original "Golden Triangle", pry drugs are commonly used to inhibit RAAS, but are prone to dry cough side effects, if not tolerated, you need to replace them with sartans.
Sakubatri valsartan is a single co-crystalline drug with good stability, high bioavailability, low adverse reactions, and can inhibit RAAS while increasing the level of natriuretic peptides, which can replace the pulfi drug as a new member of the "Golden Triangle".
<h1 class="pgc-h-arrow-right" data-track="24" >4</h1>
Prilil inhibits bradykinin degradation, which may cause dry cough and angioedema, while sacuba triacchardan can also inhibit the degradation of bradykinin, so the two cannot be combined, otherwise it will increase the potential risk. People taking ply drugs need to stop taking the drug for 36 hours before they can change their medications.
Valsartan is already included in the drug, so do not combine with other sartans.
Sakubatri valsartan has a hypotensive effect and is suitable for patients with heart failure with hypertension, but those with low blood pressure (high pressure below 100 mmHg) should be used with caution. Hyperkalemia may be caused during the course of administration, which requires monitoring of serum potassium.
Sakuba tri valsartan inhibits RAAS, which may cause renal impairment and requires monitoring of renal function during administration.
To sum up, sacobatricar valsartan is a first-line drug for the treatment of heart failure, which can also be used to treat heart failure by increasing the level of natriuretic peptides and inhibiting RAAS, and can also be used to treat hypertension. Compared with praline drugs and sartans that simply inhibit RAAS, sacobatri valsartan has a better effect on the treatment of heart failure and has lower adverse reactions. However, due to the more expensive price, it limits its wide application.
Drugs should be used under the guidance of a doctor, if you have any questions about medication, please consult a doctor or pharmacist, I am a pharmacist Huazi, welcome to pay attention to me and share more health knowledge.